State Info – Safe Biologics

ASBM Submits Comments to Oregon PDAB Opposing Proposal to Permit Automatic Substitution of Non-Interchangeable Biosimilars

December 20, 2023

On December 13, Oregon’s Prescription Drug Affordability Board (PDAB) met to consider – and ultimately rejected – a proposal to permit the automatic substitution of non-interchangeable biosimilars; that is, the substitution at the pharmacy level of a biosimilar without prescriber involvement. The automatic substitution of biosimilars is a controversial practice, banned in many countries including nearly […]

New York Becomes 36th State to Pass Biosimilar Substitution Law

November 5, 2017

On Monday, October 23rd, Governor Andrew Cuomo signed biosimilars legislation (S.4788A/A.7509A) regarding the pharmacy substitution of interchangeable biosimilar medical products—a measure ASBM and others have pursued in New York over the past two years. New York is now the 36th state to pass biosimilars substitution legislation. This law (Chapter 357 of the Laws of 2017) […]

New York Becomes 36th State to Pass Biosimilar Substitution Law

November 5, 2017

On Monday, October 23rd, Governor Andrew Cuomo signed biosimilars legislation (S.4788A/A.7509A) regarding the pharmacy substitution of interchangeable biosimilar medical products—a measure ASBM and others have pursued in New York over the past two years. New York is now the 36th state to pass biosimilars substitution legislation. This law (Chapter 357 of the Laws of 2017) […]

What a Difference a Year Makes!

November 18, 2016

Philip J. Schneider, MS FASHP Associate Dean, University of Arizona College of Pharmacy ASBM Advisory Board Chair This past weekend it was my honor to participate in a continuing education course for 100 New York pharmacists on the topic of biologic medicines and biosimilars, including safety and regulatory considerations which affect pharmacy practice. The 5-hour […]

What a Difference a Year Makes!

November 18, 2016

Philip J. Schneider, MS FASHP Associate Dean, University of Arizona College of Pharmacy ASBM Advisory Board Chair This past weekend it was my honor to participate in a continuing education course for 100 New York pharmacists on the topic of biologic medicines and biosimilars, including safety and regulatory considerations which affect pharmacy practice. The 5-hour […]

Op-Ed: Protect Patients with Open Communication

October 6, 2016

On September 30th, An op-ed appeared in the Detroit News, authored by Marcia Horn, President and CEO of the International Cancer Advocacy Network (ICAN), an ASBM Steering Committee member. Ms. Horn discusses how legislation permitting biosimilar substitution could help Michigan patients. Similar legislation has been passed in 25 states and Puerto Rico. A key provision […]

ASBM Presents at University of the Sciences in Philadelphia

September 15, 2016

On September 15th, 2016, ASBM held an educational forum at the University of the Sciences in Philadelphia (USciences). The program drew 50 attendees comprised of pharmacists, faculty members, pharmacy students. The program began with an introduction to biosimilars from USciences Associate Professor of Pharmaceutical Sciences Dr. Zhiyu Li. Dr. Li is Director of Undergraduate Pharmacology/Toxicology Program, where he […]

A Picture is worth a thousand words…

September 15, 2016

A Picture is worth a thousand words… Why Memorable Names are preferred by Pharmacists by Philip Schneider, MS FASHP Associate Dean, University of Arizona College of Pharmacy ASBM Advisory Board Chair Yesterday, I was in Philadelphia with a group of about 50 pharmacy students and faculty speaking about biosimilars and the role they do play and […]

A Picture is worth a thousand words…

September 15, 2016

A Picture is worth a thousand words… Why Memorable Names are preferred by Pharmacists by Philip Schneider, MS FASHP Associate Dean, University of Arizona College of Pharmacy ASBM Advisory Board Chair Yesterday, I was in Philadelphia with a group of about 50 pharmacy students and faculty speaking about biosimilars and the role they do play and […]

Lupus and Allied Diseases Association: Affordable access critical for care

June 18, 2016

Biosimilar drugs hold advantages for people like me, just as biologic medicines have for millions living with life-threatening and life-diminishing diseases. Access to appropriate medication can dramatically improve disease outcome and quality of life. As more biosimilars become available, we want to ensure they are safe and affordable. I strongly support S6311 and A8648A, which […]